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Thomas G. Graeber2,3,12, Caius G. Radu2,5,12, Heather Christofk2,3,12,14, Robert M. Prins1,2,12, Albert Lai12,13,
Linda M. Liau1,12, Giovanni Coppola6,13 and Harley I. Kornblum2,6,12,14*
Abstract
Background: There is considerable interest in defining the metabolic abnormalities of IDH mutant tumors to
exploit for therapy. While most studies have attempted to discern function by using cell lines transduced with
exogenous IDH mutant enzyme, in this study, we perform unbiased metabolomics to discover metabolic
differences between a cohort of patient-derived IDH1 mutant and IDH wildtype gliomaspheres.
Methods: Using both our own microarray and the TCGA datasets, we performed KEGG analysis to define pathways
differentially enriched in IDH1 mutant and IDH wildtype cells and tumors. Liquid chromatography coupled to mass
spectrometry analysis with labeled glucose and deoxycytidine tracers was used to determine differences in overall
cellular metabolism and nucleotide synthesis. Radiation-induced DNA damage and repair capacity was assessed
using a comet assay. Differences between endogenous IDH1 mutant metabolism and that of IDH wildtype cells
transduced with the IDH1 (R132H) mutation were also investigated.
Results: Our KEGG analysis revealed that IDH wildtype cells were enriched for pathways involved in de novo
nucleotide synthesis, while IDH1 mutant cells were enriched for pathways involved in DNA repair. LC-MS analysis
with fully labeled 13C-glucose revealed distinct labeling patterns between IDH1 mutant and wildtype cells.
Additional LC-MS tracing experiments confirmed increased de novo nucleotide synthesis in IDH wildtype cells
relative to IDH1 mutant cells. Endogenous IDH1 mutant cultures incurred less DNA damage than IDH wildtype
cultures and sustained better overall growth following X-ray radiation. Overexpression of mutant IDH1 in a wildtype
line did not reproduce the range of metabolic differences observed in lines expressing endogenous mutations, but
resulted in depletion of glutamine and TCA cycle intermediates, an increase in DNA damage following radiation,
and a rise in intracellular ROS.
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Conclusions: These results demonstrate that IDH1 mutant and IDH wildtype cells are easily distinguishable
metabolically by analyzing expression profiles and glucose consumption. Our results also highlight important
differences in nucleotide synthesis utilization and DNA repair capacity that could be exploited for therapy.
Altogether, this study demonstrates that IDH1 mutant gliomas are a distinct subclass of glioma with a less
malignant, but also therapy-resistant, metabolic profile that will likely require distinct modes of therapy.
Keywords: 2-hydroxyglutarate, Metabolism, Nucleotide, Radiation, Glioma
Background
Alteration in cellular metabolism is a key pathway to the
development of cancer. Most oncogenes and tumor
suppressors influence cellular metabolism, and there are
examples of mutations in metabolic genes that become
tumorigenic [1]. Homologous mutations in the metabolic
enzymes isocitrate dehydrogenase 1 and 2 (IDH1 and
IDH2) are found in acute myelogenous leukemia, colon
cancer and glioma [2]. In glioma, these mutations gener-
ally co-occur with either 1p/19q co-deletion or with muta-
tions in TP53, the former with more oligodendrocytic
characteristics and the latter with more astrocytic charac-
teristics [3]. In contrast to metabolic mutations that in-
volve a loss of function, IDH mutations were found to
bestow a new enzymatic function of reducing alpha-
ketoglutarate (a-KG) to 2-hydroxyglutarate (2-HG) [4]. In
the presence of IDH mutations, the 2-HG molecule, nor-
mally found at low levels, can increase to millimolar
amounts. Understandably, there has been considerable
interest in what role this potential “oncometabolite” might
have on cells. Given the structural similarity of the 2-HG
molecule to a-KG, it was suspected that 2-HG may be a
competitive inhibitor that blocked access to a-KG-
dependent enzymes that regulate cell epigenetics [5, 6].
There has been considerable interest in defining what
effects IDH mutations have on glioma cell biology, and
what the discovery of an IDH mutation can tell us about
a specific glioma. These questions are important for two
reasons. The first reason comes from the rationale that
if the IDH mutant enzyme changes the metabolic state
of the cell, this may render the cell more or less vulner-
able to certain types of therapy. For example, it has been
reported that the IDH1mutation makes cells more vul-
nerable to radiation [7] or NAD+ depletion [8]. This
issue has become even more clinically relevant with the
discovery that the presence of IDH mutations can be
diagnosed via imaging even prior to surgery [9]. The
second reason comes from the observation that
glioblastoma patients with IDH mutant tumors have
prolonged survival compared to patients with IDH wild-
type tumors and that there are now pharmacological in-
hibitors of the IDH mutant enzymes available that block
2-HG formation [10]. If it is the case that the IDH muta-
tion is actually a metabolic burden to the cell, then use
of these inhibitors may actually aid the tumor cell and
accelerate growth. Studies using mutant IDH inhibitors
in in vivo xenograft models have led to mixed results
with one showing slowed growth [11] and another show-
ing accelerated growth [8].
Attempts to focus on isolating metabolic differences be-
tween IDH mutant and IDH wildtype glioblastomas have
historically suffered from an unproven assumption that the
metabolic differences between IDH mutant and IDH wild-
type tumors can be largely attributed to the presence or ab-
sence of the IDH mutation itself [12, 13]. However, more
recent evidence suggests that IDH mutation may be one of
the initial mutations to occur in those gliomas [14, 15].
Large-scale bioinformatics analyses of mutational, expres-
sion and epigenetic datasets reveal that IDH mutant and
IDH wildtype tumors are different on a very fundamental
level [16] and may have different cells of origin, and differ-
ent paths of tumorigenesis. Unfortunately, attempts to
study cells derived from endogenous IDH mutant tumors
have been hampered by the difficulty involved in establish-
ing and maintaining IDH mutant glioma cells in culture.
To address these issues, we have performed a meta-
bolic analysis on a cohort of patient-derived IDH1
mutant and IDH wildtype tumor cells to determine
differences between these groups that may potentially be
exploitable for therapy. We demonstrate that when com-
pared to IDH wildtype glioma cells and tumors, IDH1
mutant cells and tumors are enriched for gene sets asso-
ciated with DNA repair, while wildtype cells have greater
expression of gene sets associated with nucleotide bio-
synthesis. IDH1 mutant cells have metabolic profiles that
are distinct from those of IDH wildtype cells and our
findings indicate that at least some of these differences
are not corrected by overexpression of mutant IDH1 in
IDH wildtype cells. Functional studies surprisingly dem-
onstrate that IDH1 mutant cells are better able to re-
cover from radiation treatment and less prone to the
effects of inhibition of de novo nucleotide biosynthesis.
These findings indicate that IDH mutant and wildtype
tumors may be responsive to different metabolically
directed therapies and that the previously held views
that IDH mutant tumors are highly radiosensitive may
not be correct for all subsets of IDH mutant tumors and
needs further exploration.
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Methods
Collection of in vitro cultures
Samples were collected under institutional review board-
approved protocols and graded by neuropathologists.
We previously reported on gene expression analysis in
these samples in all except one of the IDH mutants [17].
IDH wildtype samples were all from GBM. Of the seven
IDH1 mutant cultures, five were from GBM, one from a
grade III oligoastrocytoma and one from a grade II
oligodendroglioma. Cultures were prepared as described
previously [17]. Briefly, on the day of resection, samples
were digested with papain. Acellular debris was removed
and remaining cells were incubated in gliomasphere
media (DMEM/F12 supplemented with B27, penicillin/
ampicillin, heparin, EGF and bFGF) for several days until
spheres began to form. Frozen stocks were made at pas-
sage 5 to maintain cells at low passage. One IDH1 mu-
tant line, BT142, was obtained through ATCC [18, 19].
Relevant information pertaining to the cultures used for
in vitro experiments is summarized in Additional file 1,
which provides the characteristics of the patients and
the tumor as reported by neuropathologists as well as
data from comparative genomic hybridization and whole
exome sequencing in the samples for which it was avail-
able. The majority of experiments were performed using
the same 3 IDH WT lines (HK157, HK301, and HK308)
and 3 IDH1 mutant lines (HK213, HK252, and HK322).
Prior to the completion of data collection, the HK322
culture was lost. Therefore, two additional IDH1 mutant
lines (BT142 and HK211) were included for the radi-
ation experiments.
Whole exome sequencing and mutation analysis
Genomic DNA was extracted and fragmented by sonic-
ation using the Covaris acoustic disruptor (model E210,
Covaris Inc.) to achieve an average fragment size of 200
base pairs. Two hundred nanograms of DNA from each
sample were used for the construction of DNA libraries
using Kapa Hyper DNA library prep kits and matched
dual index adapters (Integrated DNA Technologies).
Exome capture was performed using the Nimblegen
SeqCap EZ Exome enrichment kit. Sequencing was
performed on an Illumina HiSeq 4000 following the
manufacturer’s instructions. 65–70 million 120-base,
paired-end reads were obtained per sample on average,
with a 50× average depth of coverage within the targeted
exome. Raw image files were processed with the
Illumina CASAVA 1.8 software (Illumina, San Diego, CA).
Whole exome sequencing was analyzed using the
Genome Analysis Toolkit (GATK) [20] pipeline. Briefly,
short reads were aligned using the Burrows-Wheeler
Aligner (BWA) [21]. SAMtools was used to convert be-
tween SAM and BAM file format, and Picard tools to
sort alignments and mark duplicates. Variants were
called using the GATK HaplotypeCaller function with
the following parameters: variant index parameter
128,000; variant index type LINEAR; nda; maxAltAlleles
4; ERC GVCF; contamination 0.02. ANNOVAR [22] was
used to annotate variants.
Copy number variation (CNV) analysis
DNA libraries were hybridized onto Affymetrix CytoS-
canHD arrays. We first processed the raw intensity CEL
files using the R package affy2sv [23] to generate B-allele
frequency (BAF) and log R ratio (LRR) values. Secondly,
we used the PennCNV software (parameters: exome
HMM model with gcmodel adjustment, filtered by 10
SNPs minimum 10 and with region length longer than
50 k) [24], the R package GenoCN (parameters: cnv-only
snpInfo$PFB > 1; outputSNP 1; outputSeg TRUE) [25],
and the R package Rawcopy (default parameters) [26] for
CNV inference. CNV calls were obtained by integrating
the output from all callers.
Gene set enrichment analysis
RNA was purified from 59 patient-derived gliomasphere
cultures and hybridized to Affymetrix U133 Plus 2.0
arrays. For KEGG-based analysis, we collapsed gene
expression probes based on enzyme activity (Enzyme
Commission numbers [EC]) rather than on gene identity
to avoid unequal representation of equivalent enzymatic
function within pathways, thus emphasizing potential flux
through the network. The metric used for gene ranking
was the signal to noise ratio (SNR) between the IDH1 mu-
tant and IDH1WT samples. The metric was calculated for
all candidate probesets of each gene or enzymatic activity
and the probeset with maximum absolute metric value
was retained. Probeset annotation was based on UniGene
build #201, and UniGene identifiers were mapped to each
EC using the gene names provided by KEGG. Pathways
with fewer than three or greater than 500 nodes repre-
sented by the data were excluded from the analysis. This
resulted in 167 KEGG modules in the TCGA dataset and
186 modules in the gliomasphere data set.
Glucose/glutamine uptake
200,000 cells were plated in 3 ml of gliomasphere media
and allowed to grow for 24 h. The cells were spun down
and counted, and glucose and glutamine levels in the
used media were measured using a NOVA Bioanalyzer
and compared to blank control [27–29]. To evaluate the
effects of IDH1 mutant inhibition on glucose/glutamine
uptake, 5 μM of c227 was added to the culture 24 h be-
fore being harvested.
Cell proliferation studies (CFSE)
Cell proliferation of endogenous IDH1 mutant and IDH
wildtype cultures was assessed using CFDA SE (CFSE;
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carboxyfluoresceindiacetate, succinimidyl ester) cell
tracer kit (Invitrogen) as described previously [30].
Briefly, spheres were dissociated with Accumax (Innova-
tive Cell Technologies), stained with CFSE according to
manufacturer suggestions, and grown for 5 days under
normal gliomasphere conditions at a density of 100,000
cells/mL. Preparation for FACS analysis was performed
according to manufacturer guidelines using 4% parafor-
maldehyde as a fixative. Following FACS acquisition,
Proliferation Wizard Basic Model was used to assess
proliferative populations within each sample and to gen-
erate average division times.
Liquid chromatography–mass spectrometry (LC-MS)
Cells were cultured for 24 h and rinsed with PBS, and ei-
ther unlabeled media, 50% 13C-glucose labeled media, or
50% 13C-glutamine labeled media was added. After 24 h,
cells were rinsed with ice-cold 150 mM NH4AcO (pH
7.3), followed by addition of 400 μl cold methanol and
400 μl cold water. Cells were transferred to an
Eppendorf tube, and 10 nmol norvaline (Sigma-Aldrich,
N7502) as well as 400 μl chloroform was added to each
sample. For the metabolite extraction, samples were vor-
texed for 5 min on ice and spun down, and the aqueous
layer was transferred into a glass vial and dried. Metabo-
lites were resuspended in 70% ACN and 5 μl loaded
onto a Phenomenex Luna 3u NH2 100A (150 × 2.0 mm)
column. The chromatographic separation was performed
on an UltiMate 3000 RSLC (Thermo Scientific) with
mobile phases A (5 mM NH4AcO pH 9.9) and B (ACN)
and a flow rate of 300 μl/min. The gradient ran from
15% A to 95% A over 18 min, 9 min isocratic at 95% A,
and re-equilibration for 7 min. Metabolite detection was
achieved with a Thermo Scientific Q Exactive mass spec-
trometer run in polarity switching mode (+ 3.0 kV/−
2.25 kV). TraceFinder 3.3 (Thermo Scientific) was used to
quantify metabolites as the area under the curve using re-
tention time and accurate mass measurements (< 3 ppm).
Relative amounts of metabolites were calculated by sum-
ming up all isotopologues of a given metabolite and nor-
malized to the internal standard and cell number.
Clustering analysis was done in R.
Metabolic tracing using combined liquid chromatography
and tandem mass spectrometry (LC-MS/MS)
Cell lines were grown in gliomasphere media supple-
mented with fully labeled 13C-glucose and 13C9,15N3-dC.
The cells were allowed to grow for 48 h at which point
they were harvested and lysed. Genomic DNA was
extracted using the Quick-gDNA MiniPrep kit (Zymo
Research, D3021) and hydrolyzed to nucleosides using the
DNA Degradase Plus kit (Zymo Research, E2021), follow-
ing manufacturer-supplied instructions. In the final step of
DNA extraction, 50 μL of water was used to elute the
DNA into 1.5 mL Eppendorf tubes. A nuclease solution
(5 μL; 10× buffer/DNA Degradase Plus™/water, 2.5/1/1.5,
v/v/v) was added to 20 μL of the eluted genomic DNA in
an HPLC injector vial. The samples were then incubated
overnight at 37 °C. Samples (20 μL) were injected onto a
porous graphitic carbon column (Thermo Fisher Scientific
Hypercarb, 100 × 2.1 mm, 5 μm particle size) equilibrated
in solvent A (water/acetonitrile/formic acid, 95/5/0.2, v/v/v)
and eluted (200 μL/min) with an increasing concentration
of solvent B (acetonitrile/water/formic acid, 90/10/0.2, v/
v/v) using min/%B/flow rates (μL/min) as follows: 0/0/
200, 5/0/200, 10/15/200, 20/15/200, 21/40/200, 25/50/
200, 26/100/700, 30/100/700, 31/0/700, 34/0/700, 35/0/
200. The effluent from the column was directed to the
Agilent Jet Stream ion source connected to the triple
quadrupole mass spectrometer (Agilent 6460) operating
in the multiple reaction monitoring mode using previously
optimized settings. The peak areas for each nucleosides
and nucleotides (precursor→fragment ion transitions) at
predetermined retention times were recorded using the
software supplied by the instrument manufacturer
(Agilent MassHunter). To evaluate the effects of IDH1
mutant inhibition on glucose glutamine labeling, 5 μM of
c227 was initially added to the culture and then re-added
following PBS wash.
Deoxythymidine (dT) treatment
To evaluate the effects of nucleotide synthesis inhibition,
a group of cells were grown in gliomasphere media and
subjected to 1 mM dT treatment and allowed to grow
for 4 days. At this point the cells were harvested, stained
with DAPI, and subjected to flow cytometry analysis to
determine cell cycle distribution.
Radiation
To determine the extent of DNA damage following radi-
ation, gliomaspheres were dissociated, plated at 1 × 105
cells/mL, and subjected to a 10 Gy dose of radiation using
an X-ray irradiator (Gulmay Medical, Atlanta, GA)
(5.519 Gy/min; 250 kV; a 4-mm Be, a 3-mm Al, and a 1.5-
mm Cu filter). Neutral-buffered Oxiselect Comet Assay
Kit (Cell Biolabs) was used to assess DNA damage accord-
ing to manufacturer’s instructions. For the c227 comet ex-
periments presented in Additional file 2, IDH1 mutant
cells were treated with 5 μM c227 or control for 48 h prior
to irradiation (10 Gy) and comet analysis as described
above. Radiation-induced apoptosis was measured at
4 days after treatment using TUNEL staining. To deter-
mine effects of growth following radiation, cell lines were
plated at 2 × 105 cells in 3 ml of gliomasphere media. They
were then subjected to the indicated doses of radiation (0,
2, 6, and 10 Gy) and allowed to recover for a minimum of
4 days. When the control group of each cell line was ready
to be passaged, all samples from that line were dissociated
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with Accumax (Innovated Cell Tech.), counted on a Count-
ess Automated Cell Counter (Invitrogen, C10227) using
0.4% trypan blue, and compared to the non-irradiated con-
trol group. Each bar on the graph (dose of radiation) is the
average percent of control based on a minimum of three
independent replicates (Error bars = ± SEM). The growth
curve experiments following radiation presented in
Additional file 3 were carried out in a similar manner with
the following exceptions. All cell lines were plated at an
initial density of 2 × 105 cells per 3 ml and given a single
10 Gy dose of radiation or control (0 Gy). When the fastest
growing sample was ready to be passaged, all cultures from
each group were dissociated, counted, and then replated at
2 × 105 cells. This was repeated three times in order to gen-
erate the growth curve presented in Additional file 3. Three
IDH WT and three IDH1 mutant cultures were used for
each group. Data is based on three independent replicates.
IDH1 mutant overexpression/ROS measurement
cDNA for the IDH1 mutant gene (R132H) was cloned
into a lentiviral vector and transfected into HK308 cell
line. This vector encodes a murine orthologue and was
found to maintain better and more consistent expression
of the mutant protein and 2-HG than a human vector
(data not shown). Five hundred thousand IDH1WT cells
were dissociated and plated in 3 ml of neurosphere me-
diated, infected with the lentivirus, and allowed to grow
for 2 weeks. The cells were sorted for GFP and again
allowed to grow and form spheres. All experiments were
done within 6 weeks of infection. Overexpression of the
IDH1 mutant protein was confirmed by western blot
and 2-HG measurement. IDH1 mutant and IDH wild-
type cells were allowed to grow in gliomasphere media.
They were then collected, stained with CellROX re-
agents (Thermo Fisher), and analyzed by flow cytometry.
The total ROS level was the integration of the area
under the curve as previously described [31].
Statistical analysis
Statistical analyses were performed using the GraphPad
Prism software. Sample comparisons and level of signifi-
cance were determined using the ANOVA model and
two-tailed Student’s t tests where appropriate. All quanti-
tative data presented are the mean ± standard error of the
mean (SEM) unless otherwise noted. Experiments were
performed in triplicate, with calculation of 95% confidence
interval and p values in relevant comparisons.
Results
KEGG GSEA analysis
Expression data from 59 gliomasphere lines (52 IDH
WT GBM and 7 IDH1 mutant) was subjected to Gene
Set Enrichment Analysis (GSEA) using KEGG gene
modules [32, 33]. Microarray data (GSE98995) is from
data described in Laks et al. [17]. A similar comparative
analysis was performed on IDH1 mutant and IDH WT
tumor samples in the TCGA dataset (183 IDH1WT, 19
IDH1mut). Each KEGG module was assigned a normal-
ized enrichment score (NES) for each dataset and then
plotted (Fig. 1, Additional file 4). We noted a positive
correlation between the gliomasphere and TCGA data-
sets giving confidence that our in vitro cells are a good
model for in vivo tumors.
There were fewer modules enriched in the IDH1 mutant
group in both the TCGA (37/167 gene set modules) as well
as our gliomasphere data set (50/186 gene set modules).
To identify some potential target metabolic pathways, we
used a cut-off enrichment value of 1.2. Even with this lib-
eral cut-off, we only identified four modules that were
enriched in IDH1 mutant cells in both data sets. Of these
four, the “Homologous Recombination” and “Nucleotide
Base Excision Repair” modules were selected for further
study due to the clinical relevance in terms of response to
radiation. In contrast, there were 35 modules that were
enriched in IDH WT cells (Fig. 1, Additional file 4). The
“Pentose Phosphate Pathway” and “Amino Sugar and
Nucleotide Sugar Metabolism” were selected for further
study to determine if IDH1WT cells are in fact more
dependent on the de novo pathway of nucleotide synthesis.
Metabolic profile
To assess the differences found in the expression ana-
lysis, and to investigate any further metabolic differences
between groups, a cohort of IDH WT and IDH1 mutant
lines were selected for further study. Key mutations and
CNVs of the five IDH1 mutant cultures and three IDH
WT cultures that were most intensively studied are listed
in Additional file 1. Of note, 4 of 5 of our IDH mutant
cultures had pathogenic TP53 mutations and only one
(BT142, obtained from ATCC) was 1p/19q co-deleted
(Additional file 1). Sample 322 was lost prior to detailed
analysis, but clinical cytogenetics of the primary tumor
demonstrated that it was not 1p/19q co-deleted, despite
it being an oligodendroglioma.
A cohort of 18 IDH WT and 5 IDH1 mutant cultures
were subjected to a panel of metabolic measurements in-
cluding glucose uptake, glutamine uptake, and lactate pro-
duction rates. Glucose uptake rate was significantly higher
in IDH WT cells although there was no significant differ-
ence in the lactate production to glucose uptake ratio,
suggesting that both cohorts are highly glycolytic. The net
glutamine uptake rate for all cells tested was near zero
(Fig. 2a–c). Consistent with these differences in glucose
uptake, IDH wildtype cells grew faster than IDH1 mutant
cells (Additional file 5).
To further define the different utilization of these
metabolites, we performed LC-MS on three IDH WT
(HK157, HK301, and HK308) and three IDH1 mutant
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(HK213, HK252, and HK322) lines with both fully labeled
13C glucose and fully labeled 13C glutamine. We then de-
fined a single percent label for each metabolite and per-
formed hierarchical clustering to identify if these six cell
lines naturally partitioned into groups. Consistent with the
observed differences in glucose uptake, IDH1 mutant and
IDH WT samples partitioned into separate groups when
assessed for glucose labeling (Fig. 2d). Applying hierarch-
ical clustering to the samples according to glutamine la-
beling or total metabolite amount did not distinguish the
samples into distinct groups.
Since glucose labeling could distinguish between IDH1
mutant and IDH WT samples, we performed t tests and
compiled a list of all metabolites that had an uncor-
rected p value < 0.05. Thirty-two metabolites fulfilled
this criterion of differential glucose labeling. Of these 32
metabolites, there was a significant over-representation
of nucleotide precursors (9/32 chi-square p < 0.007).
Interestingly, all of the nucleotide precursors showed in-
creased glucose labeling in the IDH WT group (Fig. 2e,
Additional file 6).
De novo versus salvage nucleotide synthesis
Because our gene expression and metabolomics results
are consistent with elevated nucleotide metabolism in
IDH WT cells, we decided to investigate further whether
IDH WT cells are more dependent on de novo nucleo-
tide synthesis than IDH1 mutant cells. We profiled the
de novo and salvage contribution to deoxycytidine
triphosphate incorporation into newly replicated DNA
using labeled 13C glucose (to denote de novo) and la-
beled [13C9,15N3]dC (to denote salvage). Using the same
set of three IDH WT lines and three IDH1 mutant lines,
we found that while all samples utilized both pathways,
the IDH WT samples used primarily de novo synthesis
while the IDH1 mutant samples used both pathways
relatively equally (Fig. 3a, b). To identify if this difference
had functional relevance, we utilized high levels of deox-
ythymidine (dT), an inhibitor of the de novo pathway
[34] to determine if there is any differential response be-
tween the two groups. Predicting that this inhibitor
would have an effect on the ability of cells to pass
through S phase, we treated cells for 4 days (~ 1 doub-
ling time) with dT and then performed cell cycle analysis
using DAPI. All cell lines showed an increase in the
number of cells in S phase; however, in the IDH1 mutant
samples, cells were better able to pass through S phase
and proceed with cell division. In contrast, at the end of
the 4-day treatment period, almost all IDH wildtype cells
were found in the S phase (Fig. 3c).
Fig. 1 KEGG Gene Set Enrichment Analysis. Plot of expression data from TCGA (167 KEGG modules) and our gliomasphere dataset (186 KEGG modules).
Each KEGG module was assigned a normalized enrichment score (NES) in either the IDH1 mutant or IDH1WT group. Each blue dot represents a
different module. The enrichment score for a particular module in the TCGA data is plotted along the X-axis and that associated with the gliomasphere
dataset for the same module is plotted on the Y-axis. Thus, a module that is highly enriched in IDH1 mutants compared to wildtype in both datasets
would be in the upper right corner and modules highly enriched in IDH wildtype in both datasets would be in the lower left hand corner. Differentially
enriched modules (NES > 1.2), listed on the right, were identified as potential candidates for further investigation
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DNA repair in response to radiation
Having discovered that GSEA expression analysis accur-
ately predicted that IDH1 mutant cells are less
dependent on de novo nucleotide synthesis than are the
IDH wildtype cells that we studied, we next turned to
the modules that we found to be enriched in IDH1 mu-
tant cells, namely modules involved with DNA repair
and cellular response to radiation. Using a comet assay,
we first tested whether there was a difference in the
amount of DNA damage incurred from a given dose of
radiation and how quickly that DNA was repaired. For
these experiments, we studied two of our IDH1/TP53
mutant lines as well as BT142, a highly studied IDH1
mutant that is 1p/19q-co-deleted but that also bears a
TP53 mutation [18, 19]. At a dose of 10 Gy, significantly
more IDH WT cells showed signs of DNA damage as
compared to IDH1 mutant cells at all time points tested
(Fig. 4a, b). In IDH1 mutant cells, DNA damage peaked
immediately after exposure to radiation, but that damage
was largely repaired within 4 h. Damage in IDH wildtype
cells peaked after the first hour post-radiation and
followed a similar trend with regard to repair. To
examine repair dynamics, we next restricted our focus
only to those cells with sustained measurable damage
(comet tails) and then calculated tail moment length at
different time points (0, 60, 120, and 240 min) to assess
which group more efficiently repairs DNA. Again, the
IDH1 mutant cultures showed significantly less initial
damage following radiation and were able to resolve DNA
breaks more quickly (Fig. 4c). However, there was no sig-
nificant difference in DNA damage between IDH1 mutant
and wildtype cells by the final time point of the assay.
We assessed the extent of apoptotic cell death using
the TUNEL assay but saw relatively low levels of TUNEL
staining and no significant difference between the two
groups (Additional file 7). However, when we examined
the ability of cells to grow after radiation, we again
found that IDH1 mutant cells were better able to re-
enter the cell cycle and divide as compared to IDH WT
cells (Fig. 4d). To ensure that these effects were not due
to differences in growth rate between IDH1 mutant and
wildtype cells, we repeated the experiment from Fig. 4d
but performed a growth curve assay over several pas-
sages to compare effects of high dose radiation (10 Gy)
on growth (Additional file 3). This analysis confirmed
that IDH1 mutants once again grow better following
radiation and are able to continue to proliferate after
several passages. Meanwhile, IDH wildtype cultures are
unable to sustain growth past the first week following this
high dose of radiation. In all, these data suggest that the
a b c
d
e
Fig. 2 Metabolic profile of IDH1 mutant and wildtype cells. a–c Quantification of glucose and glutamine consumption as well as the ratio of glucose
consumed to lactate produced. Measurements were acquired using NOVA (N= 18 IDH WT and 5 IDH1 mutant). Statistical significance was determined by
Student’s t test. d Clustering of three IDH1 mutant and three IDH wildtype lines according to LC-MS glucose labeling (IDHWTs: blue, IDH1 mutants: red). A
glucose labeling index for each of the 159 metabolites analyzed was calculated for all 6 cell lines followed by non-hierarchical clustering analysis. Each line
was run in triplicate and all samples are shown. e Quantification of glucose labeling among nucleotide precursors by group. Relative amounts of metabolites
were calculated by summing up all isotopologues of a given metabolite and normalized to the internal standard and cell number
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ab c
d
Fig. 4 IDH1 mutant cells show diminished vulnerability to radiation. a–c Assessment of DNA damage and repair by comet analysis following
irradiation (10 Gy). a Representative images of cells following comet assay. White arrows indicate cells with comets. b Graph showing the percent
of cells with comets. Comet number was calculated for each line individually and then averaged by group. c Tail moment length for each comet
was calculated as the length from the center of the comet head to the center of the tail. Tail moment length was calculated for each line individually
and then averaged by group. Significance levels were calculated by ANOVA followed by post hoc t tests. Asterisks denote p < 0.05, error bars: ± SEM.
d Quantification of the effects of increasing doses of radiation (0, 2, 6, and 10 Gy) on culture growth as described in the “Methods” section. Graphs
represent cell counts normalized to non-irradiated controls
a b
c
Fig. 3 IDH1 mutant cells utilize de novo and salvage pathways for nucleotide biosynthesis. a, b Quantification of de novo nucleotide synthesis
and salvage pathway utilization by LC-MS with labeled glucose and nucleotides. a The relative contribution of each pathway plotted in bar graph
format. b The same data plotted two-dimensionally. Error bars represent ± STDEV. c Cell cycle analysis by flow cytometry (DAPI) following 4-day
treatment with 1 mM deoxythymidine (dT) or control (left: distribution of cells in G1, S phase, and G2; right: representative histograms of cell cycle
distribution for IDH1 mutant and WT cultures following dT treatment)
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effects of radiation on growth are not simply due to
differences in growth rates between IDH wildtypes
and mutants.
IDH1 mutant overexpression as a model for IDH1 mutant
glioma
IDH1 mutant overexpression in an IDH1WT back-
ground makes those cells more vulnerable to radiation
[7]. With our new result that endogenous IDH1 mutant
cells are less vulnerable to radiation than the IDH WT
cells tested, it appeared that the IDH1 mutation itself
was not the sole determinant driving the difference be-
tween these two groups. To further test this hypothesis,
we overexpressed the IDH1 mutant protein in an IDH
WT background (HK308 + IDH1mut) and pharmaco-
logically inhibited the IDH1 mutant protein in an
endogenous IDH1 mutant cell line (HK213 + c227). We
used LC-MS to confirm 2-HG production and inhibition
respectively (Additional file 8). Once we confirmed the
appropriate effects on 2-HG production, we repeated
the glucose-uptake clustering analysis to see if this artifi-
cial IDH1 mutant line (HK308 + IDH1mut) clustered
with the IDH WT or the IDH1 mutant groups (Fig. 5a).
We found that the HK308 + IDH1mut samples clustered
with the IDH WT group and the HK213 + c227 clustered
with the IDH1mut group. More specifically, neither
IDH1 mutant overexpression nor the c227 inhibitor led
to a change in glucose labeling of nucleotide precursors
(Additional file 9). This supports the hypothesis that the
simple presence of IDH1 mutant protein or 2-HG was
not driving the difference between these two groups over
the time frames investigated.
We next investigated what effect the presence of the
IDH1 mutant protein had on cellular metabolism. We
a d
b e
c
Fig. 5 IDH1 mutant enzyme activity does not completely define the IDH1 mutant metabolic profile. a Clustering of eight samples based on
LC-MS glucose labeling as described in Fig. 2. Analysis includes the same cohorts of IDH1 mutant and wildtype cultures with the addition of
IDH1 mutant overexpression in an IDH WT line and inhibition of the endogenous mutant enzyme (308 + IDH1mut and 213 + c227 respectively).
b, c Quantification of glutamine and glucose consumption with IDH1 mutant overexpression and inhibition. d Contribution of glucose and glutamine
to 2-HG production in endogenous and transduced IDH1 mutants. e Effects of IDH1 mutant overexpression on glutamine and TCA cycle intermediates
quantified using LC-MS. p < 0.05 for all seven metabolites shown. Error bars denote ± SEM
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examined the effects on glutamine and glucose consump-
tion and found that neither the addition nor inhibition of
the endogenous IDH1 mutant enzyme influenced the con-
sumption of either metabolite (Fig. 5b, c). This was a sur-
prising result given that the expression of the IDH1
mutant enzyme leads to production of high levels of 2-
hydroxyglutarate and presumed consumption of alpha-
ketoglutarate. To investigate this further, we used LC-MS
tracing with labeled glucose and glutamine to determine
how the cell makes 2-HG. Both endogenous IDH1 mu-
tants and our overexpression model primarily used glu-
tamine to make 2-HG (Fig. 5d). However, given that we
did not observe an increase in the amount of glutamine
consumption with the addition of the IDH1 mutant gene,
we hypothesized that the cells may be depleted of glutam-
ine. Consistent with this prediction, we saw significantly
lower levels of glutamine as well as all TCA cycle interme-
diates when the IDH1 mutant gene was overexpressed
(Fig. 5e). In a recent study, Li et al. found that elevating 2-
HG levels leads to a significant accumulation of succinate
with corresponding decreases in fumarate and malate
[35]. Interestingly, we observed decreased levels of succin-
ate and increases in fumarate and malate with 2-HG
inhibition (c227) in an endogenous IDH1 mutant line
(HK213). However, this did not accurately reflect the dif-
ferences between endogenous IDH1 mutant and IDH
wildtype cells which had roughly comparable levels of glu-
tamine and TCA cycle intermediates (Additional file 10),
suggesting that the IDH1 mutation is well-compensated
for in the cells that carry it.
In order to further identify potential differences between
the endogenous IDH1 mutant and overexpression models,
as well as to help clarify differences between our observa-
tions of radiation sensitivity from previous reports [7], we
repeated our radiation experiments on HK308 with and
without overexpression of the IDH1 mutant enzyme.
Overexpression of the mutation in this IDH wildtype line
resulted in greater DNA damage and decreased repair im-
mediately following radiation (Fig. 6a–c). These results are
contrary to what was observed when comparing endogen-
ous IDH1 mutants to IDH wildtype cell lines (Fig. 4).
IDH1 mutant overexpression did, however, result in better
growth following radiation. One possible explanation for
this finding is that exogenous expression of the IDH1 mu-
tant enzyme in HK308 leads to significantly slower growth
and this may give the cell more time to repair any DNA
a d
b c
Fig. 6 IDH1 mutant overexpression does not accurately mimic the DNA repair capacity of endogenous mutants. a–c Assessment of DNA damage
and repair by comet analysis following radiation (10 Gy). a Representative images of cells following comet assay. White arrows point to cells with
comets. b Graph shows the percent of cells with comets. Comet number was calculated for each line individually and then averaged by group.
c Tail moment length for each comet is calculated as the length from the center of the comet head to the center of the tail. Tail moment length
was calculated for each line individually and then averaged by group. d Quantification of the effects of increasing doses of radiation (0, 2, 6, and
10 Gy) on culture growth as described in the “Methods” section. Graphs represent cell counts normalized to non-irradiated controls. Significance
levels were calculated by ANOVA followed by post hoc t tests. Asterisks denote p < 0.05, Error bars: ± SEM
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damage before re-entering the cell cycle. We also
investigated the effects of IDH1 mutant inhibition
(c227) on radiation-induced DNA damage and repair
(Additional file 2). This analysis did not reveal any in-
crease in DNA damage on a per cell basis, as measured by
tail moment length. Interestingly though, we did see a
more global increase in DNA damage in the c227-treated
cells as shown by the increased number of comet+ cells.
This treatment did not fully reverse the phenotype to that
of IDH wildtype, however. One interpretation of these re-
sults is that endogenous IDH1 mutants are adapted to
high levels of 2-HG which actually serve a protective role
against DNA damage. On the other hand, IDH wildtype
cells transduced with the mutant enzyme are not adapted
to the dramatically increased levels of 2-HG, resulting in
the opposite effect.
Finally, we examined the effect of the IDH1 mutant
enzyme on reactive oxygen species (ROS) levels. Inter-
estingly, studies have reported mixed results regarding
the effect of the IDH1 mutation on ROS with different
results in different cell types [36, 37]. We found that the
endogenous IDH1 mutant lines had significantly higher
ROS levels than the IDH WT lines (Fig. 7a). This ap-
pears to be due to the IDH1 mutation itself, because
when we overexpressed the IDH1 mutant enzyme in
HK308, the ROS levels increased significantly (Fig. 7b).
Discussion
Many groups have attempted to determine the effect of
the IDH1 mutation on host cells as a way to discover
metabolic vulnerabilities that may be exploited for ther-
apy. Endogenous IDH1 mutant glioma cells are difficult to
grow and maintain in culture—indeed, we lost one line
during the process of these experiments—and thus, the
first experiments to determine the effect of the IDH1 mu-
tation on cells involved exogenous overexpression of the
IDH1 mutant gene in an IDH WT background and per-
forming mass spectroscopy to find differences in the levels
of the various metabolites [13, 19, 38–40]. While many of
these studies had overlapping findings (e.g., a decrease in
glutamine and glutamate levels), other findings were more
variable and seemed to depend on the cell model being
used. Additionally, many of these in vitro differences did
not translate to ex vivo patient tumor tissue [41].
Consistent with the aforementioned studies, we also
saw a decrease in glutamine and glutamate with exogen-
ous IDH1 mutant overexpression. However, there was
no difference in glutamine, glutamate, or any TCA cycle
intermediates between IDH wildtype cells and endogen-
ous IDH1 mutant cells. This suggests that endogenous
IDH1 mutant cells may be able to compensate for many
of the effects of the IDH1 mutant enzyme itself. One
possible explanation for this is that IDH1 mutant glioma
a
b
Fig. 7 IDH1 mutant enzyme leads to higher ROS levels. a Histogram displaying ROS levels of three IDH1 mutant and three IDH1 wildtype
gliomaspheres measured using flow cytometry (CellROX Green). b Similar ROS analysis of an IDH WT line (HK308) with and without IDH1 mutant
overexpression (CellROX Deep Red). Results shown are from individual experiments. Three replicates yielded identical findings
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cells and IDH wildtype glioma cells are derived from dif-
ferent cell types with different properties. However, it is
also possible that given enough time, the exogenous
IDH1 mutant model would also be able to compensate
for the IDH1 mutant enzyme and increase its glutamine
and glutamate levels.
Another approach to determine the metabolic effect
of the IDH1 mutation on glioma cells is to inhibit
the IDH1 mutation in an endogenous IDH1 mutant
line. Both the current study and the prior study of
Tateishi et al. [8] found a mixed effect of the IDH1
mutant inhibitor on TCA cycle intermediates, with
citrate being significantly increased in both studies. In
our study, we used a relatively short incubation
period (24 h) with the c227 inhibitor in order to
isolate the differences in metabolic flux from the
changes in gene expression that are associated with
2-HG and aberrant methylation. Although the Tateishi
study did not find any significant changes in global
methylation with prolonged c227 inhibitor treatment,
they did find an increase in NADH levels likely due
to increased Naprt1 expression and NAD synthesis.
We did not see this change over our shorter time
course, and in fact, we saw decreased NADH levels
with c227 treatment.
A current challenge in IDH mutant research stems
from the variability in methodological approaches
used which can significantly alter findings. Identifying
potential shortcomings of each will greatly improve
the reliability of results. For example, by restricting
comparisons to purely isogenic cell lines with or
without IDH1 mutant enzyme overexpression or in-
hibition, the conclusions are limited to the effect of
the IDH1 mutant enzyme itself and ignore differences
between IDH1 mutant and IDH wildtype tumors that
may be independent of the IDH1 mutation. Further-
more, metabolites do not act independently but func-
tion as parts of larger pathways. Using only the total
cellular levels of various metabolites, it is difficult to
draw any conclusions about particular pathways. In
this study, we utilized multiple methods to identify
cell-type specific vulnerabilities. By using expression
data and metabolic tracing studies, we were readily
able to distinguish several pathways as well as label-
ing patterns that clearly distinguished IDH1 mutant
from IDH wildtype cells. This distinctive metabolic
signature was intrinsic to the cell itself, was retained
even with pharmacological inhibition of the IDH1
mutant enzyme, and was not seen in the exogenous
overexpression model.
Further evidence of cell culture model variability be-
tween IDH mutant studies can be seen from two add-
itional reports published during the preparation of this
manuscript, Sulkowski et al. and Lu et al. [42, 43], which
demonstrated a diminished capacity for DNA damage re-
pair in IDH1 mutant cells citing deficiencies in homolo-
gous recombination and compromised PARP-mediated
DNA repair. We observed greater DNA damage and a
similar decreased capacity for DNA repair only when
using an IDH1 mutant overexpression model. In contrast,
our results indicate greater DNA repair capacity in IDH1
mutant cells following radiation. One potential explan-
ation could be that our cultures represent only a subset of
IDH1 mutant tumors. Most, if not all, contain endogenous
IDH1 R132H mutations and mutant TP53, an important
protein that itself may play a large role in mediating many
of the observed effects independent of the IDH1 mutant
enzyme. Furthermore, the IDH wildtype GBM cultures
that were selected as controls could influence the differ-
ences observed. While both of these prior studies utilize
exogenously transduced IDH mutations, which may have
different characteristics, one report did also utilize glioma
cells with endogenous mutations for some of their key ex-
periments [42]. However, it is not clear whether these mu-
tant lines are similar to ours with respect to their other
mutations. Furthermore, the endogenous mutant cultures
from the prior report were propagated in serum, while
ours are continuously maintained in serum-free condi-
tions. The differences among these studies have important
ramifications for therapy. If, as we propose, IDH1 mutants
have a greater capacity for DNA repair following radiation,
then radiation therapy may have diminished efficacy. Fur-
ther study will be required to resolve these differences.
Many of the clinical trials that guide current treatment
protocols for glioblastoma were conducted before the dis-
covery of the IDH mutation and thus included a majority
of IDH wildtype and a minority of IDH mutant patients.
With evidence mounting that IDH mutant gliomas have
very different cellular characteristics, it is unclear whether
the results of these trials can be generalized to IDH mu-
tant tumors. In particular, the results of this study show
that IDH1 mutant gliomas are less vulnerable to
radiation-induced DNA damage which draws into ques-
tion the efficacy of radiation therapy for this subset of tu-
mors. This result was surprising when combined with the
fact that exogenous IDH1 mutant overexpression makes
cells more vulnerable to radiation [7] and that the IDH1
mutant enzyme significantly increases the amount of re-
active oxygen species in the cell. While the cytotoxic and
cytostatic mechanisms of radiation are multi-factorial,
one of the main mechanisms is DNA damage through the
indirect production of free radicals [44]. One possible ex-
planation for the decreased DNA damage seen in IDH
mutant cells following radiation is that in order to survive
this mutation, IDH mutant cells must develop buffering
mechanisms against high levels of reactive oxygen spe-
cies. This adaptation in turn could make them more re-
sistant to radiation induced DNA damage.
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The clinical evidence for the efficacy of radiation in
IDH1 mutant gliomas is mixed. In one study, IDH1 mu-
tant tumors seemed to show a better radiographic re-
sponse following radiation [45]. However, another trial
found that for supratentorial low-grade gliomas (of
which the majority are likely IDH mutant) high-dose ra-
diation had worse survival than low-dose radiation [46].
It is possible that both findings are correct and that
radiographic response may not correlate with clinical
survival. Conversely, it is possible that IDH mutant tu-
mors are maximally sensitive to low-dose radiation and
higher doses do not provide any further benefit.
Our studies of nucleotide metabolism have potential
implications for therapeutics. The availability of nu-
cleotides for DNA synthesis can be a rate-limiting
step in cellular proliferation [47]. Nucleotides are syn-
thesized through either de novo or salvage pathways.
Pharmacologically, the de novo pathway can be inhib-
ited by high concentrations of dT and the salvage
pathway can be inhibited by a novel class of com-
pounds [34]. Our data suggest that IDH1 mutant tu-
mors, in contrast to the majority of GBM, utilize this
salvage pathway and would hence require both path-
ways to be inhibited in therapeutic strategies employ-
ing inhibition of nucleotide biosynthesis.
A limitation to the current study is that, while gene
expression studies are performed using both cultured
cells and data derived directly from IDH mutant tumors
in vivo, our functional results are obtained from in vitro
studies. Very few studies have investigated a spectrum of
IDH mutant gliomas in vivo. This is undoubtedly due to
the difficulty in propagating these cells in xenograft
models. Although not shown, the cells we have utilized
did not form xenografts in immunodeficient mice, either
in the brain or subcutaneously. The reasons for this are
unknown, but suggest that the establishment of tumors
from endogenous IDH1 mutants requires host-derived
factors that are not present in our model systems. While
our findings present novel hypotheses and avenues for
future studies, some caution must be taken prior to ap-
plying our results directly to clinical trials.
Conclusions
With evidence mounting that IDH mutant gliomas
constitute a distinct subclass that follows an inde-
pendent path of tumorigenesis [48], we endeavored to
characterize metabolic differences between IDH1 mu-
tant and IDH wildtype gliomas. Our data are consist-
ent with this concept and provide evidence that some
of the distinctions may not be directly related to the
IDH1 mutation itself. Furthermore, our data suggest
that while IDH1 mutant gliomas may have a less ma-
lignant phenotype, they may also be relatively resist-
ant to certain therapies, including radiation.
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Additional file 1: Patient-derived gliomasphere culture characteristics.
Relevant patient information and clinical characteristics for the primary,
patient-derived gliomasphere cultures used in this study. Summary of
selected copy-number alterations and mutations are also shown. (PDF 42 kb)
Additional file 2: 2-HG inhibition with c227 moderately increases DNA
damage following radiation but does not reverse the IDH1 mutant
phenotype to an IDH wildtype phenotype. A-B. Assessment of DNA
damage and repair by comet analysis following irradiation (10 Gy). HK252
was treated for 48 h with 5 μM c227 or control prior to comet analysis and
compared to the IDH WT line HK157. A. Similar analysis of tail moment
length as conducted in Fig. 4. B. Graph showing the percent of cells with
comets as explained in Fig. 4. All error bars represent ± SEM. (PDF 46 kb)
Additional file 3: IDH1 mutant cells are better able to proliferate
following radiation than IDH wildtype cells. A. Growth curve following
radiation (0 and 10 Gy) shows average fold increases in cell number
between IDH wildtype and IDH1 mutant groups over three passages.
Each group consists of three IDH1 mutant and three IDH wildtype
cultures respectively. Growth curves were generated from individual cell
counts at each time point. B. Identical growth curve as shown in (A),
however, the non-irradiated groups have been removed for better visual
comparison between irradiated IDH mutant and wildtype groups. Error
bars represent ± STDEV. (PDF 51 kb)
Additional file 4: KEGG gene set enrichment analysis of IDH1 mutant
and wildtype gliomaspheres. Thirty-five modules were enriched in IDH
wildtypes compared to four modules in IDH1 mutants. (PDF 79 kb)
Additional file 5: IDH wildtype cells show faster growth rate compared to
IDH1 mutant cells. Six IDH wildtype and five IDH1 mutant gliomasphere
cultures were assessed for proliferation rate by flow cytometry using
carboxyfluorescein succinimidyl ester (CFSE). (p < 0.05). (PDF 19 kb)
Additional file 6: Glucose labeling of metabolites. Glucose fractional
contribution was computed for all 159 metabolites. Metabolites that were
significantly different between groups (uncorrected t test p < 0.05) are
shown here. (PDF 137 kb)
Additional file 7: Radiation leads to low levels of TUNEL staining in
gliomaspheres. Representative images and quantification of cells stained for
TUNEL positivity 4 days after exposure to increasing doses of radiation. There
is no significant difference between groups. Error bars represent ± SEM.
(PDF 2212 kb)
Additional file 8: IDH1 mutant overexpression leads to high levels of
2-HG and the c227 inhibitor is an effective inhibitor of 2-HG formation.
IDH wildtype gliomaspheres transduced with the IDH1 mutant enzyme
(308 + IDH1mut) and endogenous IDH1 mutant cells treated with 5 μM
c227 inhibitor (213 + c227) for 24 h are compared to their respective
controls (308 and 213) for 2-HG levels as determined by LC-MS. Data
represent the means ± SEM of three replicates per condition. (PDF 22 kb)
Additional file 9: IDH1 mutant enzyme does not affect glucose labeling
of nucleotide precursors. Cells were treated and analyzed as described for
Supporting Figure S4 in order to determine the percent labeling of
nucleotide precursors. There is no significant difference when comparing
IDH1 mutant overexpression or endogenous mutant inhibition to their
respective controls. (PDF 64 kb)
Additional file 10: Effects of pharmacologic inhibition of the IDH1
mutant enzyme on TCA cycle intermediates. Cells were analyzed as
described in Supporting Figure S5. Left: Metabolites with significantly
different percent glucose labeling of metabolites in the endogenous
IDH1 mutant line 213 treated with c227 inhibitor or control (p < 0.05).
Right: Percent labeling from endogenous IDH1 mutant and IDH wildtype
groups for metabolites that were not significantly different. (PDF 206 kb)
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